Abstract
Enrollment into clinical trials for kidney disease based on high albuminuria or low eGFR have not always yielded desired event rates. Recent data suggests that pre-trial eGFR slope may be a better tool to select trial participants. Few studies have attempted to estimate the improvement in prediction with biomarkers or a composite risk score beyond historical eGFR readings. KidneyIntelXTMis a composite risk score for DKD progression that incorporates static clinical variables and 3 plasma biomarkers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
